Glaxosmithkline Pharmaceuticals Limited

BSE: 500660 NSE: GLAXO
Glaxosmithkline Pharmaceuticals Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials and compliance.
CIN L24239MH1924PLC001151 Incorporated 13 November 1924 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: GLAXO · BSE: 500660 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹3,821.67 Cr
▲ 1.93% YoY
EBITDA · FY 2026
₹1,454.56 Cr
▲ 9.92% YoY
Net profit · FY 2026
₹1,035.98 Cr
▲ 11.69% YoY
Authorised capital
₹180 Cr
Registered with MCA
Paid-up capital
₹169.41 Cr
Issued & subscribed
Open charges
₹21.87 Cr
Satisfied ₹130 Cr
Company age
102 yrs
Est. 1924
Employees · EPFO
505
Latest available

About Glaxosmithkline Pharmaceuticals Limited

Data last updated: 08 January 2026

Glaxosmithkline Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 13 November 1924, the company has been in operation for over 102 years.

Registered with ROC Mumbai under CIN L24239MH1924PLC001151. Listed on BSE: 500660 and NSE: GLAXO.

Capital: an authorised share capital of ₹180 Cr and a paid-up capital of ₹169.41 Cr. Formerly known as British Drug Houses (India) Private Limited and British Drug Houses (India) Limited. It is led by directors including Subesh Ronald Williams and Renu Sud Karnad.

Last AGM: 27 June 2025. Financial statements filed for year ended 31 March 2025. Office: Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030.

As per the financials filed for FY 2025, the company reported a revenue of ₹3,895.14 Cr, a growth of 9% compared to the previous year.

The company has a workforce of approximately 505 employees as per the latest available data. Its group structure includes 1 subsidiary.

As per MCA filings, the company has open charges of ₹21.87 Cr and satisfied charges of ₹130 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website india-pharma.gsk.com.

Company Details of Glaxosmithkline Pharmaceuticals Limited
CIN L24239MH1924PLC001151
Registration Number 001151
Incorporation Date 13 November 1924
ROC Mumbai
Listing Status Listed (BSE: 500660, NSE: GLAXO)
Company Status Active
Date of Last AGM 27 June 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Bhushan Arun Akshikar Managing Director Juby Chandy Whole-Time Director Subesh Ronald Williams Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    india-pharma.gsk.com
  • Social Media
  • Registered Address
    Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030
  • Industry
    Pharma, Drug Formulation & Development
Company report
Glaxosmithkline Pharmaceuticals Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Glaxosmithkline Pharmaceuticals Limited report

Financials, compliance, directors, charges, ownership and filings for Glaxosmithkline Pharmaceuticals Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited has undergone 3 name changes throughout its history. The company was previously known as British Drug Houses (India) Private Limited, British Drug Houses (India) Limited, and Glaxo India Limited. The current legal name is Glaxosmithkline Pharmaceuticals Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Glaxosmithkline Pharmaceuticals Limited Current
British Drug Houses (India) Private Limited Previous
British Drug Houses (India) Limited Previous
Glaxo India Limited Previous

CIN History of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24239MH1924PTC001151. The current CIN is L24239MH1924PLC001151, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24239MH1924PLC001151 Current
U24239MH1924PTC001151 Previous

Business Activity of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is audited by M/S Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2027-07-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/S Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2027-07-31) FY 2026 Declaration of unmodified opinion

Board of Directors of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is currently managed by 9 directors, with 36 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Subesh Ronald Williams
Also directs: Glaxosmithkline Pharmaceuticals Limited
Director 07 Apr 2017 9 Years 3 Months Current
Renu Sud Karnad
Also directs: Glaxosmithkline Pharmaceuticals Limited, Eih Limited, Hdfc Bank Limited and 5 more
Director 01 Apr 2019 7 Years 3 Months Current
Bhushan Arun Akshikar
Also directs: Glaxosmithkline Pharmaceuticals Limited, Biddle Sawyer Limited, Organisation Of Pharmaceutical Producers Of India
Managing Director 01 Dec 2022 3 Years 7 Months Current
Manu Anand
Also directs: Glaxosmithkline Pharmaceuticals Limited, United Breweries Limited
Director 16 May 2022 4 Years 1 Months Current
Anup Wadhawan
Also directs: Glaxosmithkline Pharmaceuticals Limited, Yatra Online Limited, Aequs Limited and 5 more
Director 26 Mar 2025 1 Years 3 Months Current
Juby Chandy
Also directs: Glaxosmithkline Pharmaceuticals Limited, Biddle Sawyer Limited
Whole-Time Director 01 Apr 2022 4 Years 3 Months Current
Showing 6 of 9 current directors. View all directors

Financials of Glaxosmithkline Pharmaceuticals Limited FY 2026 filings available

Glaxosmithkline Pharmaceuticals Limited reported revenue of ₹3,821.67 Cr (up 1.93% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹3,821.67 Cr ▲ 1.93%
Profit · FY 2026
₹1,035.98 Cr ▲ 11.69%
EBITDA · FY 2026
₹1,454.56 Cr ▲ 9.92%
Revenue₹ Cr · Consolidated02,0004,000FY 2020: ₹3,224 Cr3,224FY 2020FY 2021: ₹3,199 Cr · -0.8% YoY3,199-0.8%FY 2021FY 2022: ₹3,278 Cr · +2.5% YoY3,278+2.5%FY 2022FY 2023: ₹3,252 Cr · -0.8% YoY3,252-0.8%FY 2023FY 2024: ₹3,454 Cr · +6.2% YoY3,454+6.2%FY 2024FY 2025: ₹3,749 Cr · +8.6% YoY3,749+8.6%FY 2025FY 2026: ₹3,822 Cr · +1.9% YoY3,822+1.9%FY 2026
Net Profit₹ Cr · Consolidated01,0002,000FY 2020: ₹93 Cr93.2FY 2020FY 2021: ₹358 Cr · +284.3% YoY358+284.3%FY 2021FY 2022: ₹1,695 Cr · +373.2% YoY1,695+373.2%FY 2022FY 2023: ₹611 Cr · -64% YoY611-64%FY 2023FY 2024: ₹590 Cr · -3.4% YoY590-3.4%FY 2024FY 2025: ₹928 Cr · +57.2% YoY928+57.2%FY 2025FY 2026: ₹1,036 Cr · +11.7% YoY1,036+11.7%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year05001,0001,500Q1'25: ₹815 Cr · +7% YoY815+7%Q1'25Q2'25: ₹1,011 Cr · +5.6% YoY1,011+5.6%Q2'25Q3'25: ₹949 Cr · +17.9% YoY949+17.9%Q3'25Q4'25: ₹974 Cr · +4.8% YoY974+4.8%Q4'25Q1'26: ₹805 Cr · -1.2% YoY805-1.2%Q1'26Q2'26: ₹980 Cr · -3.1% YoY980-3.1%Q2'26Q3'26: ₹1,041 Cr · +9.7% YoY1,041+9.7%Q3'26Q4'26: ₹995 Cr · +2.1% YoY995+2.1%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,821.67 Cr ₹3,749.21 Cr ₹3,453.71 Cr ₹3,251.72 Cr ₹3,278.03 Cr ₹3,198.86 Cr ₹3,224.38 Cr
Other Income ₹145.36 Cr ₹145.93 Cr ₹122.59 Cr ₹100.66 Cr ₹75.78 Cr ₹110.58 Cr ₹79.01 Cr
Total Income ₹3,967.03 Cr ₹3,895.14 Cr ₹3,576.3 Cr ₹3,352.38 Cr ₹3,353.81 Cr ₹3,309.44 Cr ₹3,303.39 Cr
Cost of Materials Consumed ₹436.15 Cr ₹499.9 Cr ₹545.17 Cr ₹427.48 Cr ₹611.18 Cr ₹472.02 Cr ₹474.38 Cr
Purchases of Stock-in-Trade ₹910.45 Cr ₹845.11 Cr ₹853.08 Cr ₹788.43 Cr ₹729.44 Cr ₹880.11 Cr ₹868.92 Cr
Changes in Inventories ₹4.46 Cr ₹45.85 Cr -₹63.72 Cr ₹68.96 Cr ₹15.57 Cr -₹39.43 Cr -₹35.43 Cr
Employee Benefit Expense ₹607.25 Cr ₹579.7 Cr ₹624.39 Cr ₹594.99 Cr ₹610.23 Cr ₹614.69 Cr ₹628.55 Cr
Finance Costs ₹2.73 Cr ₹1.31 Cr ₹1.8 Cr ₹1.81 Cr ₹2 Cr ₹3.53 Cr ₹6.34 Cr
Depreciation & Amortisation ₹66.44 Cr ₹66.79 Cr ₹69.68 Cr ₹65.77 Cr ₹68.19 Cr ₹79.28 Cr ₹82.68 Cr
Other Expenses ₹554.16 Cr ₹601.29 Cr ₹586.1 Cr ₹567.57 Cr ₹549.73 Cr ₹576.14 Cr ₹630.71 Cr
Total Expenses ₹2,581.64 Cr ₹2,639.95 Cr ₹2,616.5 Cr ₹2,515.01 Cr ₹2,586.34 Cr ₹2,586.34 Cr ₹2,656.15 Cr
Profit Before Exceptional Items & Tax ₹1,385.39 Cr ₹1,255.19 Cr ₹959.8 Cr ₹837.37 Cr ₹767.47 Cr ₹723.1 Cr ₹647.24 Cr
Exceptional Items ₹20.62 Cr ₹4.69 Cr -₹143.61 Cr -₹97 Lakh ₹11.58 Cr -₹172.6 Cr -₹341.49 Cr
Profit Before Tax ₹1,406.01 Cr ₹1,259.88 Cr ₹816.19 Cr ₹836.4 Cr ₹779.05 Cr ₹550.5 Cr ₹305.75 Cr
Total Tax Expense ₹370.03 Cr ₹332.3 Cr ₹226.23 Cr ₹228.76 Cr ₹398.28 Cr ₹192.35 Cr ₹212.55 Cr
Net Profit ₹1,035.98 Cr ₹927.58 Cr ₹589.96 Cr ₹610.69 Cr ₹1,694.72 Cr ₹358.15 Cr ₹93.2 Cr
  attributable to Owners - ₹0 ₹589.96 Cr ₹610.69 Cr - ₹358.15 Cr -
  attributable to NCI - ₹0 ₹0 ₹0 - ₹0 -
Other Comprehensive Income -₹7.54 Cr -₹2.66 Cr -₹4.17 Cr -₹6.04 Cr -₹1.85 Cr -₹2.05 Cr -₹3.98 Cr
Total Comprehensive Income ₹1,028.44 Cr ₹924.92 Cr ₹585.79 Cr ₹604.65 Cr ₹1,692.87 Cr ₹356.1 Cr ₹89.22 Cr
EBITDA (computed) ₹1,454.56 Cr ₹1,323.29 Cr ₹1,031.28 Cr ₹904.95 Cr ₹837.66 Cr ₹805.91 Cr ₹736.25 Cr
Basic EPS ₹54.52 ₹54.52 ₹34.83 ₹35.87 ₹22.48 ₹21.14 ₹5.50
Diluted EPS ₹54.76 ₹54.76 ₹34.83 ₹35.87 ₹22.48 ₹21.14 ₹5.50
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹4,323.87 Cr ₹4,108.08 Cr ₹3,556.62 Cr ₹3,326.58 Cr
Non-current Assets ₹539.16 Cr ₹502.19 Cr ₹544.56 Cr ₹618.36 Cr
Current Assets ₹3,784.71 Cr ₹3,605.89 Cr ₹3,012.06 Cr ₹2,708.22 Cr
Property, Plant & Equipment ₹273.51 Cr ₹269.54 Cr ₹296.8 Cr ₹294.81 Cr
Inventories ₹457.55 Cr ₹481.74 Cr ₹525.05 Cr ₹459.97 Cr
Trade Receivables ₹273.11 Cr ₹292.55 Cr ₹222.06 Cr ₹192.38 Cr
Cash & Equivalents ₹1,102.05 Cr ₹538.85 Cr ₹64.17 Cr ₹34.94 Cr
Equity (Net Worth) ₹2,284.69 Cr ₹1,951.31 Cr ₹1,777.64 Cr ₹1,741.28 Cr
Equity Share Capital ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹1,779.11 Cr ₹1,905.17 Cr ₹1,524.95 Cr ₹1,326.36 Cr
Total Liabilities ₹2,039.18 Cr ₹2,156.77 Cr ₹1,778.98 Cr ₹1,585.3 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹903.3 Cr ₹1,289.91 Cr ₹582 Cr ₹484.23 Cr ₹810.74 Cr
Investing Cash Flow ₹396.98 Cr -₹45.81 Cr ₹8.72 Cr ₹807.85 Cr -₹405.5 Cr
Financing Cash Flow -₹737.08 Cr -₹769.42 Cr -₹561.49 Cr -₹1,543.33 Cr -₹524.24 Cr
Capital Expenditure ₹55.28 Cr ₹23.02 Cr ₹31.22 Cr ₹44.04 Cr ₹34.64 Cr
Free Cash Flow (computed) ₹848.02 Cr ₹1,266.89 Cr ₹550.78 Cr ₹440.19 Cr ₹776.1 Cr
Dividends Paid ₹713.97 Cr ₹749.38 Cr ₹541.57 Cr ₹1,525.5 Cr ₹506.64 Cr
Net Change in Cash ₹563.2 Cr ₹474.68 Cr ₹29.23 Cr -₹251.25 Cr -₹119 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹995.3 Cr ₹1,041.26 Cr ₹979.94 Cr ₹805.17 Cr ₹974.37 Cr ₹949.42 Cr ₹1,010.77 Cr ₹814.65 Cr ₹929.8 Cr ₹805.26 Cr ₹956.99 Cr ₹761.66 Cr
Other Income ₹35.95 Cr ₹32.12 Cr ₹33.57 Cr ₹43.72 Cr ₹40.68 Cr ₹35.07 Cr ₹34.54 Cr ₹35.64 Cr ₹29.83 Cr ₹28.11 Cr ₹28.21 Cr ₹36.44 Cr
Total Income ₹1,031.25 Cr ₹1,073.38 Cr ₹1,013.51 Cr ₹848.89 Cr ₹1,015.05 Cr ₹984.49 Cr ₹1,045.31 Cr ₹850.29 Cr ₹959.63 Cr ₹833.37 Cr ₹985.2 Cr ₹798.1 Cr
Cost of Materials Consumed ₹113.06 Cr ₹79.9 Cr ₹115.13 Cr ₹128.06 Cr ₹115.23 Cr ₹97.48 Cr ₹148.96 Cr ₹138.23 Cr ₹204.6 Cr ₹90.95 Cr ₹91.21 Cr ₹158.41 Cr
Purchases of Stock-in-Trade ₹228.4 Cr ₹217.27 Cr ₹232.72 Cr ₹232.06 Cr ₹291.4 Cr ₹164.23 Cr ₹216.74 Cr ₹172.74 Cr ₹255.74 Cr ₹162.52 Cr ₹260.62 Cr ₹174.2 Cr
Changes in Inventories ₹2.54 Cr ₹66.65 Cr ₹7.68 Cr -₹72.41 Cr -₹54.69 Cr ₹97.45 Cr ₹18.79 Cr -₹15.7 Cr -₹93.21 Cr ₹63.37 Cr ₹2.61 Cr -₹36.49 Cr
Employee Benefit Expense ₹164.75 Cr ₹151.88 Cr ₹138.05 Cr ₹152.57 Cr ₹152.97 Cr ₹124.74 Cr ₹150.71 Cr ₹151.28 Cr ₹172.83 Cr ₹141.35 Cr ₹145.21 Cr ₹165 Cr
Finance Costs ₹61 Lakh ₹1.19 Cr ₹51 Lakh ₹42 Lakh ₹58 Lakh ₹9 Lakh ₹27 Lakh ₹37 Lakh ₹77 Lakh ₹32 Lakh ₹43 Lakh ₹28 Lakh
Depreciation & Amortisation ₹13.17 Cr ₹20.32 Cr ₹17.43 Cr ₹15.52 Cr ₹14.72 Cr ₹18.8 Cr ₹16.86 Cr ₹16.41 Cr ₹18.1 Cr ₹17.11 Cr ₹18.11 Cr ₹16.36 Cr
Other Expenses ₹135.62 Cr ₹154.22 Cr ₹150.63 Cr ₹113.69 Cr ₹136.27 Cr ₹173.6 Cr ₹153.86 Cr ₹137.56 Cr ₹132.58 Cr ₹129.01 Cr ₹167.85 Cr ₹156.66 Cr
Total Expenses ₹658.15 Cr ₹691.43 Cr ₹662.15 Cr ₹569.91 Cr ₹656.48 Cr ₹676.39 Cr ₹706.19 Cr ₹600.89 Cr ₹691.41 Cr ₹604.63 Cr ₹686.04 Cr ₹634.42 Cr
Profit Before Exceptional Items & Tax ₹373.1 Cr ₹381.95 Cr ₹351.36 Cr ₹278.98 Cr ₹358.57 Cr ₹308.1 Cr ₹339.12 Cr ₹249.4 Cr ₹268.22 Cr ₹228.74 Cr ₹299.16 Cr ₹163.68 Cr
Exceptional Items ₹0 ₹17.98 Cr ₹2.64 Cr ₹0 ₹0 ₹0 ₹4.69 Cr ₹0 ₹2.4 Cr -₹163.31 Cr ₹0 ₹17.3 Cr
Profit Before Tax ₹373.1 Cr ₹399.93 Cr ₹354 Cr ₹278.98 Cr ₹358.57 Cr ₹308.1 Cr ₹343.81 Cr ₹249.4 Cr ₹270.62 Cr ₹65.43 Cr ₹299.16 Cr ₹180.98 Cr
Total Tax Expense ₹95.24 Cr ₹104.31 Cr ₹96.51 Cr ₹73.97 Cr ₹95.7 Cr ₹78.22 Cr ₹91.31 Cr ₹67.07 Cr ₹76.14 Cr ₹19.71 Cr ₹81.65 Cr ₹48.73 Cr
Net Profit ₹277.86 Cr ₹295.62 Cr ₹257.49 Cr ₹205.01 Cr ₹262.87 Cr ₹229.88 Cr ₹252.5 Cr ₹182.33 Cr ₹194.48 Cr ₹45.72 Cr ₹217.51 Cr ₹132.25 Cr
  attributable to Owners - ₹0 ₹0 ₹0 ₹0 - - ₹0 ₹194.48 Cr ₹45.72 Cr ₹217.51 Cr ₹132.25 Cr
  attributable to NCI - ₹0 ₹0 ₹0 ₹0 - - ₹0 ₹0 ₹0 ₹0 ₹0
Other Comprehensive Income -₹13.74 Cr ₹6.2 Cr ₹0 ₹0 -₹3.84 Cr ₹1.18 Cr ₹0 ₹0 -₹69 Lakh -₹3.48 Cr ₹0 ₹0
Total Comprehensive Income ₹264.12 Cr ₹301.82 Cr ₹257.49 Cr ₹205.01 Cr ₹259.03 Cr ₹231.06 Cr ₹252.5 Cr ₹182.33 Cr ₹193.79 Cr ₹42.24 Cr ₹217.51 Cr ₹132.25 Cr
EBITDA (computed) ₹386.88 Cr ₹403.46 Cr ₹369.3 Cr ₹294.92 Cr ₹373.87 Cr ₹326.99 Cr ₹356.25 Cr ₹266.18 Cr ₹287.09 Cr ₹246.17 Cr ₹317.7 Cr ₹180.32 Cr
Basic EPS ₹16.40 ₹16.54 ₹15.07 ₹12.10 ₹15.52 ₹13.57 ₹14.67 ₹10.76 ₹11.48 ₹9.89 ₹12.84 ₹7.04
Diluted EPS ₹16.40 ₹17.45 ₹15.20 ₹12.10 ₹15.52 ₹13.57 ₹14.91 ₹10.76 ₹11.48 ₹2.70 ₹12.84 ₹7.81
Latest 12 quarters shown of 24 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹3,790.2 Cr ₹3,723.49 Cr ₹3,407.25 Cr ₹3,216.34 Cr ₹3,217.51 Cr ₹3,193.73 Cr ₹3,224.68 Cr
Other Income ₹142.56 Cr ₹142.56 Cr ₹123.48 Cr ₹101.52 Cr ₹76.22 Cr ₹110.19 Cr ₹77.56 Cr
Total Income ₹3,932.76 Cr ₹3,866.05 Cr ₹3,530.73 Cr ₹3,317.86 Cr ₹3,293.73 Cr ₹3,303.92 Cr ₹3,302.24 Cr
Cost of Materials Consumed ₹400.07 Cr ₹470.86 Cr ₹504.99 Cr ₹394.35 Cr ₹552.47 Cr ₹452.64 Cr ₹474.38 Cr
Purchases of Stock-in-Trade ₹910.44 Cr ₹845.11 Cr ₹853.08 Cr ₹788.43 Cr ₹729.44 Cr ₹880.11 Cr ₹868.92 Cr
Changes in Inventories ₹13.5 Cr ₹51.23 Cr -₹69.64 Cr ₹67.25 Cr ₹13.83 Cr -₹27.53 Cr -₹35.43 Cr
Employee Benefit Expense ₹607.25 Cr ₹579.7 Cr ₹624.39 Cr ₹594.99 Cr ₹610.23 Cr ₹614.69 Cr ₹628.55 Cr
Finance Costs ₹2.73 Cr ₹1.31 Cr ₹1.8 Cr ₹1.81 Cr ₹1.99 Cr ₹3.53 Cr ₹6.34 Cr
Depreciation & Amortisation ₹66.44 Cr ₹66.79 Cr ₹69.68 Cr ₹65.77 Cr ₹68.19 Cr ₹79.28 Cr ₹82.68 Cr
Other Expenses ₹558.74 Cr ₹607.3 Cr ₹593.78 Cr ₹571.91 Cr ₹555.71 Cr ₹578.87 Cr ₹629.81 Cr
Total Expenses ₹2,559.17 Cr ₹2,622.3 Cr ₹2,578.08 Cr ₹2,484.51 Cr ₹2,531.86 Cr ₹2,581.59 Cr ₹2,655.24 Cr
Profit Before Exceptional Items & Tax ₹1,373.59 Cr ₹1,243.75 Cr ₹952.65 Cr ₹833.35 Cr ₹761.87 Cr ₹722.33 Cr ₹646.99 Cr
Exceptional Items ₹2.64 Cr ₹4.69 Cr -₹143.61 Cr -₹97 Lakh ₹11.58 Cr -₹172.6 Cr -₹324.49 Cr
Profit Before Tax ₹1,376.23 Cr ₹1,248.44 Cr ₹809.04 Cr ₹832.38 Cr ₹773.45 Cr ₹549.73 Cr ₹322.5 Cr
Total Tax Expense ₹364.41 Cr ₹329.38 Cr ₹224.35 Cr ₹227.68 Cr ₹396.87 Cr ₹192.17 Cr ₹212.45 Cr
Net Profit ₹1,011.82 Cr ₹919.06 Cr ₹584.69 Cr ₹607.75 Cr ₹1,690.53 Cr ₹357.56 Cr ₹110.05 Cr
Other Comprehensive Income -₹7.54 Cr -₹2.66 Cr -₹4.17 Cr -₹6.04 Cr -₹1.85 Cr -₹2.05 Cr -₹3.98 Cr
Total Comprehensive Income ₹1,004.28 Cr ₹916.4 Cr ₹580.52 Cr ₹601.71 Cr ₹1,688.68 Cr ₹355.51 Cr ₹106.08 Cr
EBITDA (computed) ₹1,442.76 Cr ₹1,311.85 Cr ₹1,024.13 Cr ₹900.93 Cr ₹832.05 Cr ₹805.14 Cr ₹736.01 Cr
Basic EPS ₹59.00 ₹54.01 ₹34.51 ₹35.70 ₹22.23 ₹21.11 ₹6.50
Diluted EPS ₹59.00 ₹54.24 ₹34.51 ₹35.70 ₹22.23 ₹21.11 ₹6.50
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹4,274.91 Cr ₹4,100.93 Cr ₹3,547.8 Cr ₹3,327.7 Cr
Non-current Assets ₹553.26 Cr ₹524.57 Cr ₹573.49 Cr ₹652.51 Cr
Current Assets ₹3,721.65 Cr ₹3,576.36 Cr ₹2,974.31 Cr ₹2,675.19 Cr
Property, Plant & Equipment ₹273.51 Cr ₹269.54 Cr ₹296.8 Cr ₹294.81 Cr
Inventories ₹430.35 Cr ₹463.17 Cr ₹514.3 Cr ₹437.7 Cr
Trade Receivables ₹273.11 Cr ₹292.55 Cr ₹222.06 Cr ₹192.38 Cr
Cash & Equivalents ₹1,065.82 Cr ₹536.22 Cr ₹62.15 Cr ₹29.74 Cr
Equity (Net Worth) ₹2,241.18 Cr ₹1,949.23 Cr ₹1,784.09 Cr ₹1,753 Cr
Equity Share Capital ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr ₹169.41 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹0 ₹0 ₹0
Total Debt (computed) ₹0 ₹0 ₹0 ₹0
Current Liabilities ₹1,757.1 Cr ₹1,900.81 Cr ₹1,510.95 Cr ₹1,317.02 Cr
Total Liabilities ₹2,033.73 Cr ₹2,151.7 Cr ₹1,763.71 Cr ₹1,574.7 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹881.42 Cr ₹1,280.03 Cr ₹578.93 Cr ₹487.94 Cr ₹819.8 Cr
Investing Cash Flow ₹385.25 Cr -₹36.54 Cr ₹14.97 Cr ₹805.19 Cr -₹419.66 Cr
Financing Cash Flow -₹737.07 Cr -₹769.42 Cr -₹561.49 Cr -₹1,544.18 Cr -₹524.25 Cr
Capital Expenditure ₹55.28 Cr ₹23.02 Cr ₹31.22 Cr ₹44.04 Cr ₹34.64 Cr
Free Cash Flow (computed) ₹826.14 Cr ₹1,257.01 Cr ₹547.71 Cr ₹443.9 Cr ₹785.16 Cr
Dividends Paid ₹713.97 Cr ₹749.38 Cr ₹541.57 Cr ₹1,525.5 Cr ₹506.64 Cr
Net Change in Cash ₹529.6 Cr ₹474.07 Cr ₹32.41 Cr -₹251.05 Cr -₹124.11 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹989.15 Cr ₹1,022.59 Cr ₹973.63 Cr ₹804.83 Cr ₹966.08 Cr ₹946.36 Cr ₹1,000.05 Cr ₹811 Cr ₹910.87 Cr ₹804.98 Cr ₹953.38 Cr ₹738.02 Cr
Other Income ₹35.71 Cr ₹31.82 Cr ₹31.27 Cr ₹43.76 Cr ₹39.46 Cr ₹35.06 Cr ₹32.19 Cr ₹35.85 Cr ₹29.87 Cr ₹28.34 Cr ₹28.47 Cr ₹36.8 Cr
Total Income ₹1,024.86 Cr ₹1,054.41 Cr ₹1,004.9 Cr ₹848.59 Cr ₹1,005.54 Cr ₹981.42 Cr ₹1,032.24 Cr ₹846.85 Cr ₹940.74 Cr ₹833.32 Cr ₹981.85 Cr ₹774.82 Cr
Cost of Materials Consumed ₹101.47 Cr ₹70.1 Cr ₹107.07 Cr ₹121.43 Cr ₹108.35 Cr ₹91.93 Cr ₹137.25 Cr ₹133.33 Cr ₹192.29 Cr ₹87.52 Cr ₹79.71 Cr ₹145.47 Cr
Purchases of Stock-in-Trade ₹228.39 Cr ₹217.27 Cr ₹232.71 Cr ₹232.07 Cr ₹291.4 Cr ₹164.23 Cr ₹216.74 Cr ₹172.74 Cr ₹255.74 Cr ₹162.52 Cr ₹260.62 Cr ₹174.2 Cr
Changes in Inventories ₹6.56 Cr ₹61.71 Cr ₹10.76 Cr -₹65.53 Cr -₹53.41 Cr ₹95.28 Cr ₹22.62 Cr -₹13.26 Cr -₹98.9 Cr ₹63.93 Cr ₹9.71 Cr -₹44.38 Cr
Employee Benefit Expense ₹164.75 Cr ₹151.88 Cr ₹138.05 Cr ₹152.57 Cr ₹152.97 Cr ₹124.74 Cr ₹150.71 Cr ₹151.28 Cr ₹172.83 Cr ₹141.35 Cr ₹145.21 Cr ₹165 Cr
Finance Costs ₹61 Lakh ₹1.19 Cr ₹51 Lakh ₹42 Lakh ₹58 Lakh ₹9 Lakh ₹27 Lakh ₹37 Lakh ₹77 Lakh ₹32 Lakh ₹43 Lakh ₹28 Lakh
Depreciation & Amortisation ₹13.17 Cr ₹20.32 Cr ₹17.43 Cr ₹15.52 Cr ₹14.72 Cr ₹18.8 Cr ₹16.86 Cr ₹16.41 Cr ₹18.1 Cr ₹17.11 Cr ₹18.11 Cr ₹16.36 Cr
Other Expenses ₹140.79 Cr ₹154.05 Cr ₹150.36 Cr ₹113.54 Cr ₹136.03 Cr ₹180 Cr ₹153.78 Cr ₹137.49 Cr ₹133.6 Cr ₹132.15 Cr ₹171.55 Cr ₹156.48 Cr
Total Expenses ₹655.74 Cr ₹676.52 Cr ₹656.89 Cr ₹570.02 Cr ₹650.64 Cr ₹675.07 Cr ₹698.23 Cr ₹598.36 Cr ₹674.43 Cr ₹604.9 Cr ₹685.34 Cr ₹613.41 Cr
Profit Before Exceptional Items & Tax ₹369.12 Cr ₹377.89 Cr ₹348.01 Cr ₹278.57 Cr ₹354.9 Cr ₹306.35 Cr ₹334.01 Cr ₹248.49 Cr ₹266.31 Cr ₹228.42 Cr ₹296.51 Cr ₹161.41 Cr
Exceptional Items ₹0 ₹0 ₹2.64 Cr ₹0 ₹0 ₹0 ₹4.69 Cr ₹0 ₹2.4 Cr -₹163.31 Cr ₹0 ₹17.3 Cr
Profit Before Tax ₹369.12 Cr ₹377.89 Cr ₹350.65 Cr ₹278.57 Cr ₹354.9 Cr ₹306.35 Cr ₹338.7 Cr ₹248.49 Cr ₹268.71 Cr ₹65.11 Cr ₹296.51 Cr ₹178.71 Cr
Total Tax Expense ₹94.18 Cr ₹100.71 Cr ₹95.65 Cr ₹73.87 Cr ₹94.76 Cr ₹77.77 Cr ₹90.01 Cr ₹66.84 Cr ₹75.63 Cr ₹19.62 Cr ₹80.97 Cr ₹48.13 Cr
Net Profit ₹274.94 Cr ₹277.18 Cr ₹255 Cr ₹204.7 Cr ₹260.14 Cr ₹228.58 Cr ₹248.69 Cr ₹181.65 Cr ₹193.08 Cr ₹45.49 Cr ₹215.54 Cr ₹130.58 Cr
Other Comprehensive Income -₹13.74 Cr ₹6.2 Cr ₹0 ₹0 -₹3.84 Cr ₹1.18 Cr ₹0 ₹0 -₹69 Lakh -₹3.48 Cr ₹0 ₹0
Total Comprehensive Income ₹261.2 Cr ₹283.38 Cr ₹255 Cr ₹204.7 Cr ₹256.3 Cr ₹229.76 Cr ₹248.69 Cr ₹181.65 Cr ₹192.39 Cr ₹42.01 Cr ₹215.54 Cr ₹130.58 Cr
EBITDA (computed) ₹382.9 Cr ₹399.4 Cr ₹365.95 Cr ₹294.51 Cr ₹370.2 Cr ₹325.24 Cr ₹351.14 Cr ₹265.27 Cr ₹285.18 Cr ₹245.85 Cr ₹315.05 Cr ₹178.05 Cr
Basic EPS ₹16.23 ₹16.36 ₹14.92 ₹12.08 ₹15.35 ₹13.49 ₹14.45 ₹10.72 ₹11.39 ₹9.88 ₹12.72 ₹6.94
Diluted EPS ₹16.22 ₹16.36 ₹15.06 ₹12.08 ₹15.35 ₹13.49 ₹14.68 ₹10.72 ₹11.39 ₹2.69 ₹12.72 ₹7.71
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Glaxosmithkline Pharmaceuticals Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Glaxosmithkline Pharmaceuticals Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 75.00%, foreign institutional investors hold 4.62%, domestic institutional investors hold 7.68%, retail and other public shareholders hold 12.69% of Glaxosmithkline Pharmaceuticals Limited. The company had 121,763 shareholders on record.

Promoters: 75.00%DII (Domestic Institutional): 7.68%FII (Foreign Institutional): 4.62%Retail & Others: 12.69%
Mar 2026
QUARTER
75.00% Promoters
7.68% DII (Domestic Institutional)
4.62% FII (Foreign Institutional)
12.69% Retail & Others
Promoter holding - history
Now 75.00% · Mar 2026High 75.00% · Dec 2015Low 75.00% · Dec 2015
74%74.5%75%75.5%76%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 75.00%Mar 2016: 75.00%Jun 2016: 75.00%Sep 2016: 75.00%Dec 2016: 75.00%Mar 2017: 75.00%Jun 2017: 75.00%Sep 2017: 75.00%Dec 2017: 75.00%Mar 2018: 75.00%Jun 2018: 75.00%Sep 2018: 75.00%Dec 2018: 75.00%Mar 2019: 75.00%Jun 2019: 75.00%Sep 2019: 75.00%Dec 2019: 75.00%Mar 2020: 75.00%Jun 2020: 75.00%Sep 2020: 75.00%Dec 2020: 75.00%Mar 2021: 75.00%Jun 2021: 75.00%Sep 2021: 75.00%Dec 2021: 75.00%Mar 2022: 75.00%Jun 2022: 75.00%Sep 2022: 75.00%Dec 2022: 75.00%Mar 2023: 75.00%Jun 2023: 75.00%Sep 2023: 75.00%Dec 2023: 75.00%Mar 2024: 75.00%Jun 2024: 75.00%Sep 2024: 75.00%Dec 2024: 75.00%Mar 2025: 75.00%Jun 2025: 75.00%Sep 2025: 75.00%Dec 2025: 75.00%Mar 2026: 75.00%75.00%75.00%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters75.00%75.00%75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%25.00%25.00%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
Public25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%25.00%
Promoter change (YoY, %pts)+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00+0.00-

Board & Governance of Glaxosmithkline Pharmaceuticals Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Glaxosmithkline Pharmaceuticals Limited has 8 directors - 4 independent and 2 executive. The board is chaired by Renu Sud Karnad.

DirectorPositionOn board sinceListed boards
Renu Sud Karnad Non-Executive - Non Independent Director · Chairperson 2019-04-01 5
Sunita Maheshwari Non-Executive - Independent Director 2020-05-18 2
Manu Anand Non-Executive - Independent Director 2022-05-16 2
Somasundaram Palamadairamaswamy Non-Executive - Independent Director 2025-03-26 2
Anup Wadhawan Non-Executive - Independent Director 2025-03-26 3
Bhushan Akshikar Executive Director 2022-12-01 1
Juby Chandy Executive Director 2022-04-01 1
Subesh Williams Non-Executive - Non Independent Director 2017-04-07 1
Board Committees
CommitteeMembers
Audit Committee Somasundaram Palamadairamaswamy (Chairperson), Manu Anand, Renu Sud Karnad
Nomination and remuneration committee Manu Anand (Chairperson), Anup Wadhawan, Renu Sud Karnad
Stakeholders Relationship Committee Renu Sud Karnad (Chairperson), Bhushan Akshikar, Sunita Maheshwari
Risk Management Committee Somasundaram Palamadairamaswamy (Chairperson), Manu Anand, Renu Sud Karnad
Corporate Social Responsibility Committee Sunita Maheshwari (Chairperson), Bhushan Akshikar, Anup Wadhawan

Group Structure of Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Glaxosmithkline Pharmaceuticals Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Biddle Sawyer Limited U51900MH1948PLC006218 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Glaxosmithkline Pharmaceuticals Limited

Open charges
₹21.87 Cr
Satisfied charges
₹130 Cr
Breakdown by lending institutions
The Hongkong and Shanghai Banking Corporation Ltd.₹21.87 Cr
Latest charge details
DateLenderAmountStatus
13 Jul 1989 The Hongkong and Shanghai Banking Corporation Ltd. ₹21.87 Cr Open
20 Sep 2004 Uti Bank Ltd. ₹130 Cr Satisfied

Total charge records: 2 View all charges

Employees and EPFO Compliance at Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited has a workforce of 505 employees as of Dec 09, 2024.

Employee count
505
Active EPFO establishments
4
Employee growth
-85.4%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Glaxosmithkline Pharmaceuticals Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Glaxosmithkline Pharmaceuticals Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Glaxosmithkline Pharmaceuticals Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Glaxosmithkline Pharmaceuticals Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Glaxosmithkline Pharmaceuticals Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Glaxosmithkline Pharmaceuticals Limited

MSME Payment Delays by Glaxosmithkline Pharmaceuticals Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Glaxosmithkline Pharmaceuticals Limited

Subsidiaries & Group Companies of Glaxosmithkline Pharmaceuticals Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Glaxosmithkline Pharmaceuticals Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Glaxosmithkline Pharmaceuticals Limited

MCA Filings & Documents of Glaxosmithkline Pharmaceuticals Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Glaxosmithkline Pharmaceuticals Limited

Activity
27 Jun 2025
Glaxosmithkline Pharmaceuticals Limited last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records.
Activity
31 Mar 2025
Glaxosmithkline Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Directors
26 Mar 2025
Anup Wadhawan was appointed as a Director on 26 Mar 2025 & has been associated with this company since 1 year 3 months.
Directors
26 Mar 2025
Somasundaram Palamadairamaswamy was appointed as a Director on 26 Mar 2025 & has been associated with this company since 1 year 3 months.
Directors
01 Dec 2022
Bhushan Arun Akshikar was appointed as a Managing Director on 01 Dec 2022 & has been associated with this company since 3 years 7 months.
Directors
16 May 2022
Manu Anand was appointed as a Director on 16 May 2022 & has been associated with this company since 4 years 1 month.

Recent News on Glaxosmithkline Pharmaceuticals Limited

Frequently Asked Questions about Glaxosmithkline Pharmaceuticals Limited

Glaxosmithkline Pharmaceuticals Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 13 November 1924 (102+ years old) and is registered under CIN L24239MH1924PLC001151. Listed on BSE: 500660 and NSE: GLAXO. The company has 505 employees.

Glaxosmithkline Pharmaceuticals Limited reported revenue of ₹3,895.14 Cr for FY 2025 (up 9.00% YoY).

The current directors of Glaxosmithkline Pharmaceuticals Limited are:

The primary industry of Glaxosmithkline Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Glaxosmithkline Pharmaceuticals Limited is listed on both BSE (code: 500660) and NSE (symbol: GLAXO).

Glaxosmithkline Pharmaceuticals Limited can be reached at the registered office: Gsk House Dr Annie Besant Road Worli, Mumbai, Maharashtra, India – 400030, or through the website india-pharma.gsk.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available